P
arkinson'sdiseaseisaprogressiveneurologicalconditioncharacterizedbydegenerationofneuronsinthe substantianigraanddepletionoftheneurotransmitter dopamine. Parkinson's disease is increasingly recognized as a neuropsychiatric disorder as well as a motor disorder (Weintraub and Burn, 2011) . Dopaminergic medicationusedtotreatthemotorsymptomscanleadto thedevelopmentofneurobehaviouralsyndromes,including impulse control behaviours, which encompass impulse control disorders, dopamine dysregulation syndrome and punding (Voon et al, 2011a) . Devastating financial, psychological, legal and social consequences may ensue. This article provides practical guidance for themanagementofsuchimpulsecontrolbehaviours.
Impulse control behaviours
Impulse control disorders ImpulsecontroldisordersareagroupofpsychiatricconditionsthathavebeenrecognizedintheDiagnostic and Statistical Manual (American Psychiatric Association, 2000) . These disorders are reward-based and involve repetitiveandcompulsiveacts.Impulsecontroldisorders arecharacterizedby'afailuretoresistanimpulse,drive, or temptation to perform an act that is harmful to the person or to others'. This can result in distress and impairedsocialandoccupationalfunctioning.
The impulse control disorders commonly associated with Parkinson's disease are pathological gambling, hypersexuality,compulsiveshoppingandcompulsiveeating(alsoknownasbingeeating).Otherbehaviourshave also been reported, including hoarding, compulsive smoking,kleptomaniaandrecklessdriving.
Impulsecontroldisordersareassociatedwithdepression, novelty-seekingbehaviours,impulsivechoice,anxietyand obsessivesymptoms (Voonetal,2011a) .Thereisdebate about whether these behaviours should be categorized as behaviouraladdictionsorasobsessivecompulsivedisorders (Okaietal,2011) .Whereasobsessivecompulsivedisorder isdrivenbyattemptstoreduceanxiety,behaviouraladdictionsarebasedonthepursuitofpleasure,arousalor'need'. Both demonstrate failure to resist immediate reinforcement,despitelong-termnegativeconsequences.
Impulse control disorders have been linked with a numberofotherneurologicaldisorders,includingrestless legs syndrome and amyotrophic lateral sclerosis (Evans andButzkueven,2007; WicksandMacphee,2009 ).The greaterseverityanddifferentcharacterofimpulsecontrol disorders in Parkinson's disease compared with those in amyotrophic lateral sclerosis suggests impulse control disordersarenotcausedsimplybyresponsetoachronic neurologicaldisorder (WicksandMacphee,2009 ).
Punding, hobbyism and dopamine dysregulation syndrome
Pundingischaracterizedbystereotyped,repetitive,aimless behaviours, which can be simple (e.g. rearranging objectsorshufflingpapers) (Spenceretal,2011) or,inthe caseofhobbyism,involvemorecomplexactsassociated withaspecificactivityorhobby (Evansetal,2004) .
The activity often relates to a previous occupation or interests and may be associated with a 'soothing' effect. Thebehaviourmayinterferewithmedication,foodand sleep,andinsightintothedisruptiveandharmfulnature ofthebehaviourmaybelost.Attemptsbycaregiversor partnerstointerferewiththeactivityareoftenmetwith irritabilityoranger.
Dopaminedysregulationsyndromedescribesthecompulsive use of dopaminergic medication in Parkinson's disease patients (usually short-acting levodopa or apomorphine injections), where dosage is escalated by the patientbeyondthatrequiredtoadequatelycontrolmotor symptoms.Itisoftenassociatedwithballisticdyskinesias (Ceravolo et al, 2010) . 
Neurobiology of impulse control disorders in Parkinson's disease
The understanding of the neurobiology that underlies impulsecontroldisordersinParkinson'sdiseaseisevolving rapidly (Ceravolo et al, 2009; Ray and Strafella, 2010) .Currentevidencesuggeststhatdopamineagonists enhance learning from rewarding stimuli and outcomes and amplify impulsive choice perhaps by interference withthebalancebetweentonicandphasicdopaminergic stimulation. Impulse control disorder patients may also haveimpairedworkingmemoryandimpairedinhibition of orbitofrontal influence on enhanced ventral striatal dopamine release to reward anticipation (Voon et al, 2011a) . Functional genetic polymorphisms may also contributetoimpulsecontroldisordersensitivity.
Epidemiology of impulse control disorders
Thelargestmulticentrecross-sectionalstudyofimpulse controldisordersistheDOMINIONstudyfromNorth America.Thisreporteda6-monthprevalenceof13.6% forimpulsecontroldisorders(problemandpathological gambling5%,compulsivesexualbehaviour3.5%,compulsive shopping 5.7%, and binge eating 4.3%), with 3.9%ofpatientsexperiencingtwoormoreimpulsecon-trol disorders (Weintraub et al, 2010a) . There was a strongassociationbetweenimpulsecontroldisordersand dopamine agonist use, and a weaker association with higherlevodopadose(butnotdopamineagonistdose).
Challenges in the diagnosis of impulse control behaviours
Inclinicalpractice,impulsecontrolbehavioursappearto be under-recognized (Weintraub et al, 2009 ). Often, patients do not disclose behaviours because they are embarrassed or because they do not suspect that their medicationiscausingtheproblem.Othersmayactcovertlyinthebeliefthattheycanmanagetheirbehaviours, orbecausetheydonotwantthemtreated (Grossetetal, 2006) . Nurse specialists often receive information from family members without the patient's knowledge. Detectioncanbehelpedbyanticipatorycare (Figure 1 ).
Risk factors and the role of Parkinson's disease therapy
Parkinson'sdiseaseitselfmaymakepatientsmorevulnerabletoimpulsecontroldisorders,althoughtheextentto whichfactorssuchasexecutivedysfunctioninParkinson's disease contribute to impulse control disorder remains unresolved.Nevertheless,theriskfactorsassociatedwith developmentofimpulsecontroldisordersinpatientswith Parkinson's disease are well documented (Voon et al, 2006b (Voon et al, ,2007 Weintraubetal,2010a) (Table 1) andhighlighttheimportanceofassessingmultiplehealthdomains and psychiatric morbidity in patients with Parkinson's diseaseandimpulsecontroldisorders (Voonetal,2011b) . Impulsecontroldisordershavebeenreportedasaclass effectofalldopamineagonists.Generally,thedailydoses ofdopamineagonistsarehigherinpatientswithimpulse controldisordersthaninthosewithout (Weintraubetal, 2006) .However,impulsecontroldisordershavealsobeen reportedinpatientstreatedwithlowdosesofdopamine agonists in restless legs syndrome that is not associated withParkinson'sdisease (EvansandButzkueven,2007) .
Theremaybeanindividualthresholdforimpulsecontrol disorder behaviour in terms of dopamine agonist dose (Macpheeetal,2009 (Molina et al, 2000; Weintraub et al, 2010b; Walsh and Lang, 2012) . Individual cases reporting links between impulse controldisordersandmonoamineoxidaseinhibitorsand catechol-O-methyltransferaseinhibitorsexistbutarerare.
Many patients with mild impulse control behaviours find their behaviour non-intrusive or non-deleterious (Ondo and Lai, 2008) , and others may consider their behaviour their only pleasure, a factor which must be considered before clinical intervention. In Parkinson's disease,a'continuum'ofbehaviour,fromapathyassociated with hypodopaminergic stimulation to impulse controldisorderprovokedbyexcessoraberrantdopaminergic stimulation, may be conceptualized.The clinician must carefully assess the impact of impulse control behavioursondailylivingandotheractivitiesandshould reviewtheconsequencesofthebehavioursbeforeintervention.Thedegreeofdistresstothepatientandfamily should also be weighed, appreciating that disparity of views(oftenasaresultoflackofinsight)maybetaxing indeterminingthemostethicalcourse. Figure 1 presentsanalgorithmforthemanagementof impulse control behaviours. The article now reviews strategiesforthemanagementofimpulsecontrolbehav-iours and provides a brief recommendation on each strategy that reflects the consensus opinion of the authors, acknowledging the paucity of robust evidence. Theoveralltreatmentbenefitmustbedeterminedjudiciously;e.g.withdrawalofdopamineagonistsorswitchingtherapiesmaybenefitimpulsecontrolbehaviourbut bedetrimentaltomotorsymptoms(Case study 1).
Dopaminedysregulationsyndromeshouldhavesimilaranticipatorycaremeasuresasimpulsecontroldisorder. Red flags to dopamine dysregulation syndrome includeearlyorseveredyskinesiaandreportsof'running out'ofmedication.Tominimizeexcessdosing,patients with dopamine dysregulation syndrome may require surveillancemeasuressuchasGPandpharmacychecks andensuringpatientsarenotobtainingalternativesupplies of levodopa (e.g. from the internet or other patients), particularly short-acting preparations such as Madopardispersibleandrescueapomorphineinjections.
Antipsychotic drugs, such as quetiapine or clozapine, mayberequiredtocontroldopamine-inducedpsychosis or mania or, in extreme cases, impactful pathological gamblingorhypersexuality.
Anticipatory care and the management of impulse control behaviours
Beforeprescribingdopamineagonists,patientsandcaregivers should be advised of the potential for dopamine agoniststocauseimpulsecontroldisordersandexcessive daytimesomnolence (Grossetetal,2010) .TheScottish IntercollegiateGuidelineNetworkguidelines(Grossetet al, 2010) recommend written documentation of such conversationsandadvisesignpostingpatientsandcarers tovalidatedmaterials,suchastheParkinson'sUKwebsite. Clearly, a balanced discussion of the benefits and risksoftreatmentiscrucial.Individualpatientsandcarers may differ in their assessment of the benefit:risk ratio, Monitor for dose escalation ¶ * Preferably with written information, at initiation of dopaminergic therapy (particularly with dopamine agonist drugs), of the risk of impulse control disorders (increased or changed gambling, shopping, eating or sexual behaviours) and other disinhibitory behaviours, such as punding or excess hobbyism. † Particularly depression. Liaise with appropriate specialist team for assessment and management. Impulse control disorders may be precipitated by affective disorders. ‡ Young age, males, and people with past or family history of addictive behaviours or excess alcohol use. Be vigilant, as many of the behaviours are covert and kept hidden from family and health-care professionals. § Review patient and gain validated background information from carers at each clinical review as impulse control disorders and dopamine dysregulation syndrome may become apparent at any time during treatment. Increase vigilance during dose titration. ¶ Warn carers and pharmacists regarding the need to monitor for escalation or ingestion of levodopa-based therapies beyond recommended doses (dopamine dysregulation syndrome). Monitor for hoarding or craving. Review number of 'rescue' doses of soluble levodopa or intermittent apomorphine. ** Assess with the patient and carers the degree of distress and the impact behaviours are having -recognizing that there is a 'continuum' of behaviour -and then decide whether intervention or ongoing monitoring at this time is necessary; review comorbidities, particularly neuropsychiatric issues. † † If on a dopamine agonist, consider reduction cautiously to determine possible dose 'threshold' at which impulse control disorder behaviour and 'urge' may resolve. Consider partial substitution of total dopamine agonist dosage with levodopa but review continually for 'transformation' of impulse control disorder into dopamine dysregulation syndrome behaviour. ‡ ‡ If behaviour continues, the best evidence indicates dopamine agonist withdrawal and making levodopa therapy core treatment. § § Monitor for development of dopamine agonist withdrawal syndrome in patients with impulse control disorder most at risk. Dopamine agonist withdrawal syndrome symptoms are similar to those of drug-withdrawal syndrome: anxiety, panic, sweating, fatigue, pain, orthostatic hypotension, depression, dysphoria and drug craving. ¶ ¶ Consider adjunctive drug therapy; however, most reports on this are anecdotal and some are contradictory. Selective serotonin-reuptake inhibitor treatment is advised if patient has mood disturbance; it may also help some aspects of compulsive behaviour but may worsen impulse control disorder. Anecdotal reports for topiramate, quetiapine, clozapine, zonisamide, sodium valproate (may worsen motor signs) and amantadine -both improvement and increased risk have been reported. *** Consider cognitive behavioural therapy -emerging but limited evidence suggests that cognitive behavioural therapy may benefit patients with impulse control disorder. † † † Consider practical measures to deal with behaviours, such as relatives holding credit cards when gambling an issue, blocking access to the internet and voluntary blocking at bookmakers. ‡ ‡ ‡ In refractory and severe problems, consider deep brain stimulation surgery with reduction in dopaminergic therapy; however, variable results have been reported. If further dopamine agonist therapy is considered necessary or appropriate, consider a switch to an alternative dopamine agonist-patch or sustained-release therapy (evidence limited). Note that both improvements and precipitation of impulse control disorder have been reported from studies on the use of continuous apomorphine and Duodopa. 
Dopamine agonist reduction or cessation
Managementofimpulsecontroldisordersbyreductionor cessation of dopamine agonists (with a concomitant increase in levodopa dose, if necessary) has been investigated in three long-term observational studies (Mamikonyanetal,2008; Macpheeetal,2009; Sohtaoglu etal,2010 
Case Study 1
A 57-year-old man was diagnosed with Parkinson's disease in 1996 and commenced treatment with selegiline and pergolide. Following an episode of paranoid psychosis in 2001, treatment was changed from pergolide to pramipexole. Levodopa was commenced in 2003 and slowly titrated upwards, and entacapone was added in 2004 following some decline in motor symptoms. Later that year, the patient's partner reported problematic hypersexuality. Entacapone was withdrawn, whereupon the patient's behaviour returned to normal. In 2007, the patient's partner discovered that he had significant credit card debts from online gambling. Pramipexole was rapidly down-titrated and stopped, but levodopa monotherapy was continued as the patient needed to remain mobile.
In 2009, the patient described his motor symptoms as intolerable. Rotigotine was commenced with regular reviews. Motor symptoms improved considerably and there was no evidence of impulse control disorders or neuropsychiatric concerns disclosed 8 months later although regular monitoring and review is being undertaken as relapse of behaviour remains possible. Recommendation: during reduction or cessation of dopamine agonist therapy, patients with impulse control disorders should be closely monitored for deterioration of motor control and the emergence of withdrawal symptoms or the development of other impulse control behaviours, such as dopamine dysregulation syndrome.
Route of dopamine agonist administration
The route and nature of dopaminergic administration may have a role in treatment complications. Evidence fromseveralstudies (Honigetal,2009; Martinez-Martin etal,2011; Trenkwalderetal,2011) suggeststhatcontinuous dopamine stimulation achieved by continuous drug delivery via intrajejunal levodopa, subcutaneous apomorphineortransdermalrotigotinecanimprovethe non-motorsymptomsofParkinson'sdisease. Therapiesthatdonotachievecontinuousdopamine stimulation (e.g. levodopa or dopamine agonist) may excessively activate the 'reward centre' (nucleus accumbens),thussensitizingtherewardpathway(ventral striatum). In support of this, Parkinson's disease patients with dopamine dysregulation syndrome have greater ventral striatal dopamine agonist release in responsetolevodopastimulationthanpatientswithout dopaminedysregulationsyndrome (Evansetal,2006) . A similar increase in ventral striatal dopamine was recordedinresponsetopulsatiledopaminestimulation in a positron emission tomography study in patients with pathological gambling (Steeves et al, 2009 ).This suggeststhatusinglongeractingtherapiesattheinitiationoftherapymayreducetheriskofimpulsecontrol disorders.PreliminarydatafromtheEUROPARstudy (373 patients from several centres across Europe) suggestthat,comparedwithshorteractingdopamineagonists, rotigotine therapy appears to have a low rate of emergentimpulsecontroldisorderanddiscontinuation of therapy (Rizos et al, 2012) . Controlled studies are currentlyunderway(AAntonini,personalcommunication, 2012) but at this stage there is insufficient evidence to make specific recommendations for which preparation should be used when starting dopamine agonisttherapy.
Pharmacological management
Anumberofpharmacologicalstrategieshavebeenstudied for the management of impulse control behaviours. Selective serotonin-reuptake inhibitors may be effective intreatingimpulsecontrolbehavioursinnon-Parkinson's disease patients (Kim et al, 2002) .There is preliminary evidence from two small randomized controlled studies thattopiramateandamantadinemayassistinthetreatmentofimpulsecontrolbehavioursinParkinson'sdisease patients (Bermejo,2008; Thomasetal,2010) although amantadinehasalsobeenimplicatedinimpulsecontrol disorders (Weintraubetal,2010b) .
The opioid antagonist naltrexone has been used to treat pathological gambling in non-Parkinson's disease populations (Kim,1998; Grantetal,2008) ;aphaseIV 8-week study has investigated its effectiveness against impulsecontroldisordersinParkinson'sdiseasepatients and the results are awaited (Clinicaltrials.gov, 2013) . Assessmentandtreatmentofadjunctiveneuropsychiatric disorders,suchasanxiety,panicattacks,depressionand hypomania, is important as these disorders may 'drive' impulsecontrolbehaviours.
Recommendation: there is limited evidence for the use of adjunctive pharmacotherapy in impulse control disorder but detection and treatment of concurrent psychopathology, such as depression, may be helpful in managing impulse control behaviour.
Deep brain stimulation
Overtime,dopaminergictherapymaybecomelesseffective in treating the motor symptoms associated with Parkinson's disease. Deep brain stimulation, commonly ofthesubthalamicnucleus,canreducemotorsymptoms and permit a reduction in dopaminergic therapy (Demetriadesetal,2011 
Case Study 2
A male patient was diagnosed with Parkinson's disease at 45 years of age and commenced treatment with levodopa. He was prescribed selegiline 1 year later but did not tolerate it, so he was switched to dopamine agonists. The patient was admitted to psychiatric care following an acute psychotic episode, whereupon dopamine agonists were stopped and he was treated with escalating doses of levodopa monotherapy for several years. The patient was unable to tolerate catechol-O-methyltransferase inhibitors. In 2004, he received an apomorphine challenge and was prescribed intermittent injections, during which time there was a marked improvement in his Parkinson's disease. Intermittent injections soon escalated to seven-eight per day and the patient was switched to an apomorphine pump. In 2007, the patient was changed to Duodopa, which significantly improved his lifestyle and quality of life. However, approximately 1 year later his spouse reported uncontrollable dyskinesias, resulting in weight loss and friction burns. The Duodopa dose was decreased by two-thirds, but Parkinson's disease control was poor. A rotigotine patch was co-administered for overnight control. In 2008, his partner reported compulsive shopping, at which point Duodopa and rotigotine doses were reduced, which relieved this impulse control disorder. However, the patient began to experience compulsive eating, although this was not problematic as the patient had previously lost weight.
Practical strategies
Practical measures implemented by the caregiver (and supportedbyParkinson'sdiseasespecialistnurses)might be initiated at the start of dopamine agonist therapy. These can include monitoring medication compliance, reportingimpulsecontroldisorderbehavioursandtaking controlofinternetaccessandthefinancialaffairsofthe patient.
Recommendation: practical measures, particularly in relation to finances and internet access, are useful in patients with impulse control behaviours, as is family education and support by Parkinson's disease nurse specialists.
Psychological strategies
Psychological interventions, including cognitive behaviouraltherapy,maybeusefulinmanagingimpulsecontrol behaviours in non-Parkinson's disease populations (Dowlingetal,2006; Mulleretal,2013 
KEY POINTS
n Impulse control behaviours are increasingly recognized as serious complications of dopaminergic therapy in Parkinson's disease. n Impulse control behaviours encompass impulse control disorders (such as pathological gambling, hypersexuality, binge eating and compulsive shopping), punding and dopamine dysregulation syndrome. n Patients with impulse control behaviours may face devastating financial, psychological, legal and social consequences. n Impulse control behaviours appear to be under-recognized in clinical practice.
Detection can be aided by anticipatory care. n Clinicians managing patients with Parkinson's disease should regularly enquire about non-motor symptoms and impulse control behaviours because these may not be declared to family or health professionals routinely. n Management by reduction or cessation of dopaminergic therapy should include close monitoring for the deterioration of motor control and the emergence of withdrawal symptoms or the development of other behaviours. n Other therapeutic management strategies include adjunctive pharmacotherapy and deep brain stimulation, although further evidence is required. n Practical management strategies (e.g. in relation to finances) and psychological interventions (e.g. cognitive behavioural therapy) may be useful.
